Fortress Biotech, Inc.
FBIO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.93
KIRA · Stoqly’s AI analyst, in plain words
- Fortress Biotech, Inc. had $63.3M of revenue in fiscal 2025, up 9.7% on the year before. Over five years, revenue changed +6.8% a year on average.
- Its operating margin was −111.0%, up 80.4 pts: of every 100 in sales, about −111 is left after running the business.
- Fortress Biotech, Inc. made $6.8M of net profit in fiscal 2025.
- Fortress Biotech, Inc. returned $0.7M to shareholders in fiscal 2025. The diluted share count rose 34.2%.
- Fortress Biotech, Inc. has $24.9M more cash than debt.
Market cap
$61.4M
P/E
0.7x
Revenue
$63.3M
Net income
$6.8M
Free cash flow
—
Operating margin
−111.0%
Fortress Biotech, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+9.7%
Yes. Sales grew 9.7% last year.
Does it make a profit?
10.8%
Yes. It keeps 10.8% of every sale as profit.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
0.7x
One share costs 0.7 times its yearly profit per share.
What Fortress Biotech, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Fortress Biotech, Inc.
- CIK
- 0001429260
Fortress Biotech, Inc. · FBIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $68.8M | $75.7M | $84.5M | $57.7M | $63.3M |
| Revenue growth | 50.9% | 10.1% | 11.6% | −31.8% | 9.7% |
| Gross margin | 53.4% | 59.4% | 72.9% | 63.8% | 66.9% |
| Operating margin | −274.1% | −268.8% | −168.4% | −191.4% | −111.0% |
| Net income | −$64.7M | −$86.6M | −$60.6M | −$46.0M | $6.8M |
| Net margin | −94.1% | −114.3% | −71.7% | −79.8% | 10.8% |
| Diluted EPS | −$0.79 | −$15.97 | −$8.47 | −$2.69 | −$0.07 |
| Cash | |||||
| Cash from operations | −$117M | −$179M | −$128M | −$80.2M | −$65.8M |
| Capital expenditure | $4.6M | $2.7M | $0.1M | $0.0M | — |
| Free cash flow | −$121M | −$182M | −$128M | −$80.2M | — |
| FCF margin | −176.0% | −240.4% | −151.8% | −139.0% | — |
| Dividends paid | $0.7M | $0.7M | $0.7M | $0.7M | $0.7M |
| Share count change | 13.5% | −92.7% | 36.9% | 156.3% | 34.2% |
| Debt and strength | |||||
| Cash and short-term investments | $306M | $178M | $80.9M | $57.3M | $79.4M |
| Debt incl. finance leases | $42.9M | $91.7M | $60.9M | $58.0M | $54.5M |
| Shareholders' equity | $109M | $41.7M | $22.5M | $22.7M | $49.9M |
| Current ratio | 3.4x | 1.8x | 1.4x | 1.3x | 2.5x |
| Interest coverage | −12.3x | −16.3x | −9.3x | −8.2x | −6.9x |
| Returns and quality | |||||
| Return on capital | — | — | −4,547.1% | −372.1% | −222.0% |
| Return on equity | −61.9% | −115.1% | −188.7% | −203.2% | 18.8% |
| Return on tangible equity | −67.3% | −651.4% | −3,042.5% | — | −8.5% |
| Piotroski F-score | 2 | 3 | 2 | 1 | 5 |
| Altman Z'' | −3.0 | −9.2 | −17.8 | −20.9 | −12.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Fortress Biotech, Inc. · FBIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.93 a share, the company is worth $61.4M: 0.7 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001429260). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.